François Mongrain, CPA CA

Vice President Finance & Chief Financial Officer

François Mongrain has more than 20 years of financial experience centered on technology, growth-oriented businesses. During his 9 years in Entrepreneurial Services and Merger & Acquisition at Ernst & Young, he worked with several technology companies primarily active in the health care sector.

Following his Ernst & Young years, he became a founding partner of BridgeCapital Inc., a private consulting firm offering strategic and financial expertise to biotechnology companies. Through his years at E&Y and BridgeCapital, Mr. Mongrain played instrumental roles in more than 12 start-ups and participated in several IPO and private placements for young emerging companies.

Prior to Mimetogen, Mr. Mongrain co-founded Innodia, a biotech company focusing its R&D activity in developing novel drug for the treatment of diabetes and obesity. As Vice President Finance & CFO and then Chief Operating Officer, he successfully financed the Company’s research & development operations over a six-year period prior to orchestrating the sale of the Company to a publicly-listed Canadian biotechnology Company.

François received a Bachelor of Commerce degree from the Ecole des Hautes Etudes Commerciales (Montreal) and earned his Charted Accountant designation with Ernst & Young in 1993.

Read More »
Karen Meerovitch, PhD

Vice President, Clinical Development

Karen Meerovitch has over 20 years of experience in drug discovery and development in the pharmaceutical and biotechnology industry. At Mimetogen, Dr. Meerovitch started as the Company’s Senior Scientist and now serves as Vice President, overseeing all CMC, non-clinical, clinical and regulatory development activities of tavilermide.

Prior to joining Mimetogen, she was Group Leader for all preclinical activities at Avance Pharma (Laval, Quebec). Prior to that she was Senior Scientist at Shire Biochem (Laval, Quebec), where she was a key contributor in the discovery and research of several projects in oncology drug discovery programs in the area of angiogenesis, apoptosis, and vascular targeting. Dr. Meerovitch holds an appointment as Adjunct Professor at McGill University in the Department of Pharmacology and Therapeutics. She is author or co-author of over 20 publications and reviews.

Dr. Meerovitch holds a B.Sc. and PhD. from McGill University and an M.Sc. from the University of Alberta, all in Biochemistry. She also completed her post-doctoral fellowship in the Department of Medicine at McGill University.

See More »